top of page
< Back

Obinutuzumab

奧妥珠單抗

Mechanism of action:

Obinutuzumab 是一種第二代抗 CD20 的 IgG1 單株抗體（anti-CD20 monoclonal antibody）。Obinutuzumab 的標靶為 B 細胞表面的 CD20 抗原。Obinutuzumab 的 Fc 在設計上對於 FcγRIIIa（CD16）受體的親和力高，當 obinutuzumab 結合至 B 細胞相關惡性腫瘤後，能促進自然殺手細胞（NK cell）與巨噬細胞（macrophae）介導的毒殺作用。

​Reference(s):

1. Owen C et al. (2012). Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther. 


2. Cartron G et al. (2017). Obinutuzumab: what is there to learn from clinical trials? Blood. 


3. Davies A et al. (2022). Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Future Oncol.

bottom of page